[1]Chahal HS, Marseille EA, Tice JA, et al. Cost-effectiveness of early treatment of hepatitis C virus genotype 1 by stage of liver fibrosis in a US treatment-naive population[J]. JAMA Intern Med, 2016, 176(1):65-73.
[2]Hakuno D, Kimura M, Ito SHepatokine, et al. α1-Microglobulin signaling exacerbates inflammation and disturbs fibrotic repair in mouse myocardial infarction[J]. Sci Rep, 2018, 8(1):16749.
[3]Nakao T, Arii S, Kaido T, et al. Heparin accclcrates liver regeneration following portal branch ligation in normal and cirrhotic rats with increased plasma hepatocyte growth factor levels[J]. J Hepatol, 2002,37(1):87-92.
[4]Yan Y, Guan C, Du S, et al. Effects of enzymatically depolymerized low molecular weight heparins on CCl4-induced liver fibrosis[J]. Front Pharmacol, 2017, 8:514.
[5]Tripodi A, Primignani M, Braham S, et al. Coagulation parameters in patients with cirrhosis and portal vein thrombosis treated sequentially with low molecular weight heparin and vitamin K antagonists[J]. Dig Liver Dis, 2016, 48(10):1208-1213.
[6]Kim WR, Berg T, Asselah T, et al. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients [J]. J Hepatol, 2016, 64(4):773-780.
[7]Hui J, Gao J, Wang Y, et al. Panax notoginseng saponins ameliorates experimental hepatic fibrosis and hepatic stellate cell proliferation by inhibiting the Jak2/Stat3 pathways[J]. J Tradit Chin Med, 2016, 36(2):217-224.
[8]潘旭旺, 童永喜, 庄让笑, 等. 芹菜素纳米乳抗CCl-4诱导大鼠肝纤维化作用实验研究[J]. 中华中医药学刊, 2017, 35(6):1482-1485.
[9]Adatya S, Sunny R, Fitzpatrick MJ, et al. Coagulation factor abnormalities related to discordance between anti-factor Xa and activated partial thromboplastin time in patients supported with continuous-flow left ventricular assist devices.[J]. J Heart Lung Transplant, 2016, 35(11):1311-1320.
[10]Annika W, Victoria A, Debashis H, et al. CD248/endosialin critically regulates hepatic stellate cell proliferation during chronic liver injury via a PDGF-regulated mechanism:[J]. Gut, 2016, 65(7):1175-1185.
[11]Cerini F, Vilaseca M, Lafoz E, et al. Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats [J]. J Hepatol, 2016, 64(4):834-842.
[12]Simonetto DA, Yang H, Yin M, et al. Chronic passive venous congestion drives hepatic fibrogenesis via sinusoidal thrombosis and mechanical forces [J]. Hepatology, 2015, 61(2):648-659.
[13]Papatheodoridis GV, Papakonstantinou E, Andrioti E, et al. Thrombotic risk factors and extent of liver fibrosis in chronic viral hepatitis [J]. Gut, 2003, 52(3):404-409.
[14]徐列明. 中医药抗肝纤维化疗效评价的探索[J]. 临床肝胆病杂志, 2017, 33(5):825-828. |